Human CD20 Stable Cell Line - CT26

Name: Human CD20 Stable Cell Line - CT26
SKU: CSC-RO0610
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0610

Host Cell : CT26 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Cat. No.	CSC-RO0610
Description	This cell line is derived from CT26 and is engineered to stably overexpress Human CD20.
Target Gene	CD20
Gene Species	Homo sapiens (Human)
Host Cell	CT26
Host Cell Species	Mus musculus (Mouse)
Applications	1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation
Size	>1x10⁶ frozen cells/vial
Stability	Validated for at least 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Storage	Liquid nitrogen
Shipping	Dry ice

Revival

Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Quick Inquiry

Background

Applications

Q & A

Customer Reviews

The Human CD20 gene encodes a cell surface glycoprotein that is highly expressed on the surface of B lymphocytes, particularly in mature B cells and B cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). CD20 is a key marker for B cell identity and is a target for several monoclonal antibodies used in the treatment of B cell malignancies.

The CT26 cell line, derived from a murine colon carcinoma, is a useful model for studying cancer biology and for the development of cancer therapies. By stably expressing the human CD20 gene, the CT26 cell line provides a platform for investigating the role of CD20 in B cell biology and for evaluating the efficacy of CD20-targeted therapies. This cell line is particularly valuable for studying the mechanisms of action of anti-CD20 antibodies and for drug screening in the context of B cell malignancies.

The Human CD20 Stable Cell Line - CT26 is a colon carcinoma cell line that has been engineered to express the CD20 protein, a surface marker found on B cells and used as a target for B cell depletion therapies in autoimmune diseases and certain types of cancer.

（1）Autoimmune Disease Research:

CD20 is a well-established target for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The CT26 CD20 Stable Cell Line can be used to study the effects of CD20-targeted therapies on B cell depletion and the subsequent impact on disease progression.

（2）Cancer Therapy Development:

In addition to its role in autoimmune diseases, CD20 is also a target in B cell malignancies. This cell line can be used to test the efficacy of CD20-targeted therapies, such as monoclonal antibodies or CAR-T cell therapies, in eliminating cancer cells.

（3）B Cell Function and Signaling Studies:

The expression of CD20 in the CT26 cell line provides a model to study the role of this protein in B cell function, including its involvement in cell cycle regulation, differentiation, and apoptosis. Researchers can use this cell line to investigate the molecular mechanisms underlying B cell behavior and to identify potential therapeutic targets.

Customer Q&As

What experimental design considerations are crucial when utilizing the Human CD20 Stable Cell Line - CT26 to evaluate the efficacy of anti-CD20 monoclonal antibodies?

A: When utilizing the Human CD20 Stable Cell Line - CT26 to evaluate anti-CD20 monoclonal antibodies' efficacy, it's essential to include both negative and positive controls to validate the assay's specificity and sensitivity. A non-transfected CT26 cell line should serve as a negative control, whereas a well-characterized anti-CD20 antibody can be used as a positive control. Optimizing antibody concentrations and incubation times is critical for distinguishing between effective and ineffective antibodies. Flow cytometry should be used to quantitatively assess CD20 expression and antibody binding, ensuring cells are properly stained and analyzed under consistent conditions.

How can the Human CD20 Stable Cell Line - CT26 be utilized to investigate the mechanisms of action of CD20-targeted therapies?

A: To investigate the mechanisms of action of CD20-targeted therapies using the Human CD20 Stable Cell Line - CT26, researchers can perform a series of assays that dissect the pathways involved in drug action. This includes assessing cell viability post-treatment using assays such as MTT or Annexin V/PI staining to determine apoptotic and necrotic cell death. Co-culturing the cell line with immune effector cells, such as natural killer cells, can elucidate antibody-dependent cellular cytotoxicity (ADCC) mechanisms. Additionally, complement-dependent cytotoxicity (CDC) assays can be performed by adding human complement serum post-antibody treatment. These experiments provide insights into how CD20-targeted therapies induce tumor cell death.

Which methods should be employed to verify the stable expression of CD20 in the Human CD20 Stable Cell Line - CT26 over extended culture periods?

A: To verify the stable expression of CD20 in the Human CD20 Stable Cell Line - CT26 over extended culture periods, periodic validation using flow cytometry is recommended. This involves staining the cells with a fluorescently labeled anti-CD20 antibody and analyzing the percentage of CD20-positive cells. Quantitative PCR (qPCR) can also be used to measure the transcript levels of CD20, ensuring the gene's expression remains consistent. It's advisable to perform these checks at various passages to monitor for any potential drift in CD20 expression. Additionally, Western blotting can be utilized to assess the protein levels of CD20, providing a comprehensive view of its expression stability.

What considerations must be taken into account when adapting the Human CD20 Stable Cell Line - CT26 for in vivo studies in murine models?

A: When adapting the Human CD20 Stable Cell Line - CT26 for in vivo studies in murine models, several considerations must be addressed. First, ensure the murine model is immunocompromised to prevent immune rejection of the humanized cells. Selecting an appropriate model, such as NSG or NOD-SCID mice, is critical for successful engraftment. Secondly, monitoring for potential immunogenicity of the human CD20 expressed on CT26 cells is essential, as it might elicit an immune response. Additionally, establishing optimal cell inoculation numbers and routes of administration (e.g., subcutaneous, intravenous) is crucial for replicating disease pathology accurately. Lastly, ethical considerations and institutional guidelines for animal care and use must be strictly followed.

How can the impact of genetic background on the expression and function of CD20 in the Human CD20 Stable Cell Line - CT26 be assessed?

A: Assessing the impact of genetic background on the expression and function of CD20 in the Human CD20 Stable Cell Line - CT26 requires a comparison with other cell lines or the same cell line with different genetic backgrounds. This can be achieved by introducing specific genetic modifications using CRISPR/Cas9 or other gene-editing tools to alter genes that may interact with CD20 expression or function. Subsequent analyses, including flow cytometry for CD20 surface expression and functional assays such as ADCC or CDC, can elucidate the role of these genetic factors. Additionally, RNA sequencing (RNA-Seq) could be employed to identify differential gene expression profiles that may influence CD20's role in these cell lines.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Customer Reviews

Consistent CD20 Expression

The Human CD20 Stable Cell Line - CT26 maintains consistent expression of the CD20 protein, crucial for reliable experimental outcomes. This consistent expression ensures that the results of studies conducted using this cell line, particularly those involving the behavior and interaction of CD20, are reproducible and dependable.

United Kingdom

2021-12-23

Enhanced Cellular Stability

Stability is a key feature of the Human CD20 Stable Cell Line - CT26, where the cell line shows high resilience and uniformity over extended cultures. This stability is important for conducting experiments that require long-term cell growth without the loss of phenotype or function.

Germany

2021-06-19

Optimized for Antibody Testing

This cell line is optimized for testing and developing anti-CD20 antibodies, a common therapeutic approach in conditions like lymphoma and leukemia. The Human CD20 Stable Cell Line - CT26 provides a robust platform for evaluating the efficacy of antibodies in binding and neutralizing CD20, crucial for therapeutic antibody development.

French

2021-07-15

High Transduction Efficiency

The Human CD20 Stable Cell Line - CT26 exhibits high transduction efficiency, making it easier to introduce additional genetic elements if needed. This feature is particularly useful for us looking to study gene function in the context of CD20 expression or to create more complex disease models.

United States

2024-03-22

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

Name

Country *

Email *

Related Products

Cat.No.	Product Name	Price
CSC-RO0065	Mouse 4-1BB Stable Cell Line-CHO-K1	Inquiry
CSC-RO0113	Human PDCD1LG2 Stable Cell Line-HEK293T	Inquiry
CSC-RO0062	Mouse TLR11 Stable Cell Line-HEK293T	Inquiry
CSC-RO0011	Human CD274 Stable Cell Line-CHO-K1	Inquiry
CSC-RO0045	Human CD47 Stable Cell Line-CHO-K1	Inquiry
CSC-RO0100	Human CTLA4 Stable Cell Line-HEK293T	Inquiry
CSC-RO0080	Human CD28 Stable Cell Line-HEK293T	Inquiry
CSC-RO0002	Human CD276 Stable Cell Line-CHO-K1	Inquiry
CSC-RO0012	Human CD274 Stable Cell Line-HEK293T	Inquiry
CSC-RO0046	Human TNFRSF4 Stable Cell Line-CHO-K1	Inquiry

Human CD20 Stable Cell Line - CT26

Cell Line Information

Cell Culture Information

Safety and Packaging

Background

Applications

Q & A

Customer Reviews

What experimental design considerations are crucial when utilizing the Human CD20 Stable Cell Line - CT26 to evaluate the efficacy of anti-CD20 monoclonal antibodies?

How can the Human CD20 Stable Cell Line - CT26 be utilized to investigate the mechanisms of action of CD20-targeted therapies?

Which methods should be employed to verify the stable expression of CD20 in the Human CD20 Stable Cell Line - CT26 over extended culture periods?

What considerations must be taken into account when adapting the Human CD20 Stable Cell Line - CT26 for in vivo studies in murine models?

How can the impact of genetic background on the expression and function of CD20 in the Human CD20 Stable Cell Line - CT26 be assessed?

Consistent CD20 Expression

Enhanced Cellular Stability

Optimized for Antibody Testing

High Transduction Efficiency

Related Products

Related Services